Commercial Space Company Risk / Opportunity Ranking

Thesis: Recent very large funding, high stated valuation, and evidence of expanding sovereign SAR demand support a durable multi-quarter scaling thesis.

Why now: On June 9, 2026 ICEYE disclosed a €450 million primary Series F at valuation above €10 billion, with total round size above €1 billion including secondary, and later June context also referenced a €300 million revolving credit facility and additional sovereign satellite demand; those are recent business-state signals for a 1 year+ horizon.

Caveats: Some support is supporting article context rather than company-specific positive evidence. Several supporting demand/customer references are undated, so recency is uncertain for those claims.

Thesis: SpaceX has the strongest evidence-set-backed long-horizon opportunity because it secured multiple large, recent government awards that deepen its role as a core military and civil space infrastructure provider, with contract scope spanning surveillance, communications backbone, and additional NASA crew missions.

Why now: The timing is supported by late-May 2026 contract awards: a $2.29 billion Space Force data-network award dated May 26, 2026 and a $4.16 billion Space Force SB-AMTI award dated May 29, 2026/May 30, 2026, plus NASA's plan dated May 24, 2026 to add missions to SpaceX's commercial crew contract, all of which indicate durable backlog expansion and franchise entrenchment over a 1 year+ horizon.

Caveats: The reviewed sources' available source fields contain no direct positive or negative events for SpaceX; opportunity is inferred from high-materiality neutral facts and article summaries. Ticker mapping is noisy in the reviewed sources: SpaceX is shown with ticker TSLA, which should not be treated as validated public-company identity here.

Thesis: Apex has the strongest opportunity case in this screen because multiple dated June 2026 sources say it raised over $200 million at a $2.3 billion valuation specifically to scale high-rate satellite bus production for proliferated constellations, and a separate dated June 2026 article says Northrop partnered with Apex on space-based interceptors for Golden Dome. Together, these indicate fresh capital, scaling intent, and positioning with government/defense demand vectors over a 1 year+ horizon.

Why now: Why now is strong because the key financing evidence is dated June 5, 2026 and the Northrop partnership article is dated June 1, 2026, making both recent within the 90-day recent evidence window and relevant to a 1 year+ scaling thesis. The June 5 financing event is later than the April 16 capacity/context article and therefore better reflects current business state.

Caveats: Most available evidence is neutral fact or supporting article context, not explicit positive events. Same-day repeated articles around the fundraise are not independent proof beyond corroboration. Some context sources are company-issued or article-level summaries, which are weaker than direct events.

Thesis: AST SpaceMobile has strong long-horizon opportunity because it achieved a critical regulatory milestone for a 248-satellite direct-to-device constellation and continues to show ecosystem buildout through operator partnerships and stated constellation scale targets.

Why now: The key timing event is the FCC authorization dated April 21, 2026/April 22, 2026 granting authority for up to 248 satellites and direct-to-device service, a milestone that can unlock U.S. commercial and government use cases over a 1 year+ horizon. Later-dated company-site context on June 23, 2026 also says AST has nearly 60 operator partners and targets direct broadband to standard smartphones.

Caveats: Much of the evidence is company, press-release, or article-context based rather than independent hard performance metrics. The reviewed sources cites a target of 45 to 60 BlueBird satellites by end-2026 in article summary context, but this is not available as a direct structured fact here.

Thesis: BlackSky has the strongest recent opportunity evidence in the screen: a multi-year sole-source $99 million U.S. government IDIQ tied to next-generation Earth observation and space domain awareness development, plus a separate $25 million multi-year assured contract with a major international defense customer. Together these indicate current government demand, product validation, and longer-horizon backlog/ARR support.

Why now: The why-now is supported by two dated recent wins inside the recent evidence window: on March 31, 2026 BlackSky said it received a multi-year sole-source $99 million U.S. government IDIQ and initial $2 million funding for advanced large-aperture payload design; on April 22, 2026 it announced a competitive $25 million multi-year assured contract with a major international defense customer and said it had four Gen-3 satellites on orbit and was rapidly deploying Gen-3 capacity while driving up backlog and annual recurring revenue.

Caveats: The $99 million figure is an IDIQ ceiling, not fully funded revenue at announcement; only an initial $2 million was specifically disclosed. Some corroboration repeats the same underlying announcement and should not be treated as independent evidence

Thesis: Boeing has the strongest opportunity evidence in this screen because the reviewed sources includes recent company-linked fact evidence that it won a $2 billion U.S. Space Force contract to build two next-generation MUOS communications satellites. The award covers design, development, production, testing, and on-orbit support for a critical military SATCOM network, with launches no earlier than 2031 and 2032 and constellation support through 2035. That is a material, durable space/defense win aligned with the 1 year+ horizon

Why now: Why now is strong because the contract was reported on June 23-25, 2026, making it recent within the 90-day recent evidence window, and it represents a fresh, material U.S. defense-space award with multiyear strategic relevance

Caveats: Some corroborating rows are supporting article context and should not be overcounted as independent confirmation. Program financial benefits may phase in over a long cycle given first delivery timing in 2031.

Thesis: Capella Space has the strongest opportunity profile in this screen because the reviewed sources includes a dated, company-specific contract fact showing it won a roughly $49 million SDA contract to build two satellites for a military communications demonstration, adding to evidence that it operates advanced SAR satellite capabilities and serves government and strategic customers.

Why now: The April 8, 2026 SDA award is recent within the recent evidence window and is directly relevant to a 1 year+ horizon because it funds spacecraft design and development for a government demonstration program. Later context articles in April-June 2026 continue to depict Capella as an operating SAR platform with defense exposure.

Caveats: The positive contract evidence is classified as a neutral supporting fact in the reviewed sources, so direction is inferred from the business substance rather than explicit positive polarity labeling. Several contextual articles mention a planned acquisition or subsidiary status, but time-sensitive ownership/public-status interpretations should be treated cautiously because not all such references are direct, dated transaction-closing evidence. For example, and

Thesis: Impulse Space has the strongest opportunity setup in this screen based on recent, company-linked financing evidence that it raised $500 million in Series D funding to scale production of orbital transfer vehicles, with article context also indicating expansion to support growing commercial and government demand. For a 1 year+ horizon, that capital base can support production scale-up and program execution.

Why now: The catalyst is recent and dated: on June 2, 2026/June 3, 2026, Impulse Space disclosed a $500 million Series D and total capital raised above $1 billion, which is highly relevant for a 1 year+ scaling thesis.

Caveats: Some supportive items are supporting article context and should not be treated as independent confirmation if repeating the same financing announcement. Older commercial contract and government contract references in representative articles are outside the 90-day recent evidence window and therefore not primary recency support here.

Thesis: Katalyst Space Technologies has a strong opportunity profile because the reviewed sources show recent evidence of both mission relevance and financing: a NASA Phase III SBIR contract to develop a rescue concept for the Neil Gehrels Swift Observatory and a later June 23, 2026 report that it raised $12 million to develop its NEXUS robotic spacecraft and expand satellite servicing.

Why now: Why now is strong because the latest dated evidence on June 23, 2026 adds new capital after the May 29, 2026 NASA-related mission context, supporting a 1 year+ thesis that the company is moving from concept credibility toward funded development in on-orbit servicing.

Caveats: Part of the positive case comes from company-issued materials and supporting article context rather than independent positive evidence. The May 29, 2026 article includes a dated source date but describes an announcement text beginning 'August 11, 2025'; chronology should therefore be read carefully, with the treated as the recency marker for this retrieved item. Citation

Thesis: Northrop Grumman has the strongest reviewed sources-supported opportunity profile in this screen due to multiple recent space-defense catalysts: inclusion in the April 8, 2026 Andromeda RG-XX awards, a June 1, 2026 partnership with Apex on Golden Dome space-based interceptors, and a June 22, 2026 $398M Space Force contract for the Enhanced Protected Tactical SATCOM Prototype. Together these support a durable 1 year+ defense-space demand thesis.

Why now: The setup is current and cumulative: April 8, 2026 Andromeda participation, June 1, 2026 Golden Dome interceptor partnership, and June 22, 2026 award of a $398M protected satcom contract all fall within the 90-day recent evidence window and point to sustained momentum.

Caveats: The reviewed sources does not provide direct business impact breakdowns beyond the $398M contract article. Some support is supporting article context rather than dated events.

Thesis: Observable Space has the strongest positive setup in this screen because the reviewed sources contain dated evidence that it raised a $90 million Series A and secured a $94 million U.S. Space Force optical-systems contract, supporting capital availability, customer validation, and potential multi-quarter execution runway.

Why now: The timing is favorable because on May 28, 2026 the company was reported to have both closed a $90 million Series A and announced a $94 million U.S. Space Force award, with additional follow-on reporting on June 9, 2026 indicating the contract landed just weeks after the raise, suggesting a recent step-change in funding and government traction for a 1 year+ horizon

Caveats: Positive direction is inferred from neutral facts plus article summaries; the reviewed sources does not provide explicit positive events. Same-article repeated rows are not independent confirmation. Supporting web-search evidence is context and should be treated below directly cited company evidence.

Thesis: PLD Space has recent financing, strategic customer/investor validation, infrastructure investment, and a first commercial launch contract, all of which support a durable launch-scaling thesis over the next year-plus.

Why now: The reviewed sources show a sequence of material developments: €180 million Series C on March 4, 2026, €30 million EIB venture debt signed April 7, 2026 and reported May 6, 2026/04-07, first commercial contract reported May 21, 2026, and €35 million Kourou launch-complex investment on June 1, 2026 while MIURA 5 remained on track for a late-2026 first test flight. That is strong state-change evidence for a 1 year+ horizon.

Caveats: Risk evidence is partly inferred from dependency on future launch milestones rather than a disclosed adverse event. Most support is supporting article context, though the chronology is consistent and material.

Thesis: Quantum Space has the clearest evidence-backed opportunity profile in this screen: within the recent evidence window it announced a SPAC merger expected to bring substantial capital and public-market access, and later won a Pentagon-funded orbital refueling spacecraft contract built on its Ranger platform. Those developments support a durable 1 year+ thesis around funding access, national-security positioning, and product relevance in on-orbit logistics.

Why now: The evidence is recent and sequenced: on June 8, 2026 Quantum Space announced its planned SPAC merger and expected Nasdaq listing under QSPC

Caveats: Most available evidence is external overlay context rather than first-party positive or negative events. Same-theme repetition across June articles is not independent confirmation. Ticker QSPC is prospective after the expected SPAC close per June 8, 2026 evidence, not confirmed as already trading under that symbol

Thesis: True Anomaly has the strongest opportunity profile in this screen because the reviewed sources contain dated, company-linked evidence that it raised $650 million in Series D financing at a $2.2 billion valuation on April 28, 2026 and was selected by the U.S. Space Force for the Space-Based Interceptor program on May 4, 2026. For a 1 year+ horizon, that combination of fresh capital plus program participation supports scaling, product development, and defense-space positioning.

Why now: The recent sequence matters: on April 28, 2026, True Anomaly announced a $650 million Series D at a $2.2 billion valuation, also. Then on May 4, 2026, a dated article said the company was selected by the U.S. Space Force Space Systems Command for the Space-Based Interceptor program. That capital-plus-program sequence is directly relevant to a long-horizon growth thesis.

Caveats: Most evidence is external overlay context/facts rather than primary data source direct events. Several sources repeat the same April 28 financing story and are not independent confirmation of different events. The company-site article is undated, so recency-sensitive claims from it should be treated cautiously.

Thesis: Anduril has a credible 1 year+ opportunity setup from recent participation in major U.S. defense-space programs and fresh financing context. Recent article context says Anduril was among companies awarded Space Force Andromeda contracts for the RG-XX satellite effort on April 8, 2026, and a later article says Anduril raised a $5B Series H round published June 19, 2026, supporting capital availability for scaling in defense-space programs.

Why now: The timing is supported by recent 2026 article context around Space Force Andromeda participation and the June 19, 2026 financing context, which together suggest active momentum over the last quarter.

Caveats: Most evidence is weak context-only article evidence, not direct positive events in the available ranking rows.

Thesis: Astroscale has the clearest 1 year+ opportunity setup in this screen: within the recent evidence window article context shows recent funding support, strategic growth financing for medium-to-long-term expansion, and a shift from demos toward repeatable commercial missions, including defense-related servicing and a 2027 inspection mission pipeline.

Why now: Recency is the main reason: on June 22, 2026 SpaceNews said Astroscale was 'working to transition from technology demonstrations to a regular series of missions, bolstered by a recent capital infusion' and saw 'repeatable business opportunities' particularly among defense customers. On May 19, 2026 financing materials said the company would raise 30.6 billion yen to secure medium-to-long-term growth funding 'in anticipation of transitioning to a phase of continuous order acquisition'. On April 6, 2026 Astroscale revealed its ISSA-J1 mission scheduled for launch in 2027.

Caveats: Most within the recent evidence window evidence is supporting article context, not structured company-specific events; reviewed sources warns supporting article context is weaker than direct event/fact evidence. Same-article repeated weak-context rows are not independent confirmation. Older 2023 and 2025 articles exist in representative articles but fall outside the 90-day recent evidence window for ranking use.

Thesis: Best opportunity profile in this screen based on multiple dated article-context items showing the company remains active in in-orbit servicing/debris removal, has financing support, is ramping toward ClearSpace-1, and is expanding into defense-adjacent partnership activity. For a 1 year+ horizon, that combination supports a credible strategic growth and market-positioning thesis.

Why now: Why now is supported by recent dated context: on June 24, 2026, SpaceNews reported ClearSpace signed an MOU with Shield Space to develop sovereign space defense capabilities for the UK and allies, indicating adjacent market expansion. On May 19, 2026, the company site said it had finalized a EUR 26.7 million Series A and was ramping operations ahead of ClearSpace-1 scheduled to launch in 2026. These dated items fit a 1 year+ horizon because they point to ongoing commercialization and mission preparation.

Caveats: Most evidence is supporting article context, not direct positive events. The financing article published on May 19, 2026 references January 19, 2023 for the Series A round, so funding recency versus page recency should not be conflated.

Thesis: Cowboy Space has the strongest positive evidence in this screen: a large Series B financing at a substantial valuation, explicit plans to build vertically integrated rockets plus orbital data-center infrastructure, and stated hiring/buildout activity. That combination supports a durable 1 year+ strategic opportunity thesis.

Why now: Multiple dated articles on May 11, 2026 report Cowboy Space raised $275 million in Series B financing at a $2 billion valuation to build rockets with orbital data-center upper stages, and a TechCrunch article says the company is standing up its own rocket program with a first launch expected before end-2028

Caveats: The reviewed sources contain no explicit negative event evidence; risk is inferred from execution complexity and long timeline, not from adverse events. Several supporting rows repeat the same May 11, 2026 financing story and are not independent confirmation. Some supporting article context is undated and should be treated cautiously for recency.

Thesis: Dawn Aerospace has the strongest opportunity evidence in this screen because a recent dated company article says it closed a $25 million Series B at a $195 million post-money valuation to accelerate global expansion of reusable space transportation. The funding is directly tied to rollout, commercial scaling in the US and Europe, and support for an expanding international customer base, which fits a 1 year+ horizon.

Why now: The key catalyst is recent and explicit: on June 16, 2026 the company announced the Series B close and said the proceeds will finance global rollout and scaling of commercial and operational teams in the US and Europe.

Caveats: Evidence comes from a company-published article, so it is not fully independent. No direct structured positive event row is provided beyond supporting article context.

Thesis: Eutelsat has a strong long-horizon opportunity case from the reviewed sources' membership rationale stating it is supervising a 264-satellite IRIS2 element and won a €350M French defense satellite contract with sovereign LEO capacity. That combines infrastructure scale with government-backed demand.

Why now: The reviewed sources' membership rationale cites current program/contract relevance through support articles 2026-04, and: but were not provided in the payload, limiting precise timing narration.

Caveats: The reviewed sources does not provide for the membership-support article IDs. Opportunity score is tempered by the absence of kept direct evidence in the ranking payload.

Thesis: No material adverse thesis is supported either. The reviewed sources only provides thin acquisition-context mention, so risk remains low-scored for lack of evidence rather than comfort.

Why now: No 90-day article summaries or evidence were available for COMSAT in these reviewed sources, so there is no supported timing catalyst.

Caveats: Relations/context-only style mention should not be used as counterparty propagation evidence. Phase2 rationale references article ids: and: but no or summaries are provided in the reviewed sources. No direct evidence were available after recent evidence window.

Thesis: No material adverse thesis can be supported from these reviewed sources because no direct negative evidence are provided within the recent evidence window.

Why now: There is no usable company-specific evidence in the reviewed sources after recent evidence filtering; coverage data shows zero article IDs after recent evidence window and zero evidence available, so there is no current catalyst basis in these reviewed sources.

Caveats: Absence of evidence is not positive evidence. Reviewed evidence notes only weak peer-group context in phase2 rationale, but no citable article details are included in the scoring fields.

Thesis: No material adverse company-specific evidence is provided. The primary risk is simply that the evidence is too indirect to support a real thesis.

Why now: No in-recent evidence window article summary or evidence row was available for Cosmoserve, so there is no supported catalyst timing.

Caveats: The mention is article-level and indirect rather than company-specific. Phase2 rationale references article id: but no or summary is included. No direct evidence were available after recent evidence window.

Thesis: No retained 90-day negative evidence supports a risk thesis.

Why now: The reviewed sources retains zero evidence after the recent evidence filter, leaving no current catalyst or recency-supported business update.

Caveats: Only one historical article was considered and none are retained within the recent evidence window. The single membership support item is not enough for a current directional call. This is effectively a watchlist placeholder until newer evidence appears.

Thesis: No material adverse evidence is available. The main risk is evidentiary weakness: supplier-beneficiary framing without direct contract, backlog, or financial evidence leaves the thesis unproven.

Why now: Potentially relevant if broader space spending is increasing, but the reviewed sources provide no retained dated evidence, no current data, so timing and magnitude cannot be validated.

Caveats: No current evidence is provided for Relation/context evidence must not be used as counterparty propagation; reviewed sources notes context only. No available direct evidence after recent evidence window despite high article count considered.

Thesis: No material negative evidence is retained in the reviewed sources.

Why now: The reviewed sources rationale says Deloitte launched satellites for Project Constellation to test on-orbit cyber protections and contracted Spire to design, build, and operate satellites, citing article, but no or retained evidence row is available after recent evidence window, limiting confidence.

Caveats: The described activity comes only from membership rationale rather than retained evidence. Without retained dated evidence or, chronology and durability cannot be tested.

Thesis: No retained 90-day negative evidence supports a material risk call.

Why now: Despite several historical mentions, the reviewed sources show zero retained article IDs and zero evidence after recent evidence filtering, so there is no recent catalyst evidence in the served data.

Caveats: Historical support mentions approximately $50M funding, but the underlying evidence is not retained within the current recent evidence window reviewed sources. Low scores reflect missing current evidence, not a negative operating judgment.

Thesis: No direct adverse evidence is provided in the reviewed sources. The main issue is lack of current evidence within the recent evidence window, so risk cannot be ranked highly.

Why now: There is no strong 'why now' because coverage data shows zero article IDs after recent evidence window and zero evidence after recent evidence window, so any thesis would be under-supported for current timing.

Caveats: No evidence remained after the 90-day recent evidence window. Phase-2 membership rationale is not enough for a directional thesis by itself. Recency and business-state claims are unavailable in the reviewed sources.

Thesis: No material adverse thesis is supported. The main issue is lack of substantiated company-specific evidence.

Why now: No available article summaries or evidence exist after recent evidence window for DPhi Space in these reviewed sources, so there is no supported why-now catalyst.

Caveats: Support level is only provisional_single_article_context in the reviewed sources. Phase2 rationale references article id, but no or summary is included. No evidence were available after recent evidence window.

Thesis: Despite broad defense and geopolitical exposure implied by context, the reviewed sources have no direct negative evidence within the recent evidence window, so no adverse thesis is supportable.

Why now: Membership rationale references articles: and, but coverage data shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. unavailable in reviewed sources.

Caveats: Large mention volume is not conviction. Defense-space context is not directional proof. Referenced have no in the reviewed sources.

Thesis: No direct adverse evidence is retained, but the company is especially thinly covered in these reviewed sources, which raises uncertainty rather than a demonstrable risk case.

Why now: Why now is absent because only 2 articles were considered and none survived the 90-day filter; there is no current evidence basis for a 1 year+ directional call.

Caveats: Coverage is extremely sparse. The only described relation is context/service oriented and relations are context-only unless policy-gated. No post-cutoff evidence available.

Thesis: No material adverse evidence is available within the reviewed sources' recent evidence window.

Why now: There is no available within the recent evidence window evidence row after the March 29, 2026 cutoff; coverage data shows zero article IDs after recent evidence window and zero evidence after recent evidence window for Emposat.

Caveats: Phase-2 membership rationale references articles and, but the reviewed sources provide no for citation. Ground-station context is indirect and not enough for a strong thesis under the evidence standard.

Thesis: No material adverse evidence is provided in the reviewed sources after recent evidence filtering, so a negative thesis is unsupported.

Why now: Why now is unsupported because no evidence remain after recent evidence filtering; there is no dated catalyst, financing, contract, production, or customer evidence available here.

Caveats: No surviving evidence after recent evidence filtering. Reviewed evidence counts indicate evidence existed upstream, but none is included here for direct citation. Low scores reflect missing evidence, not a fundamental negative judgment.

Thesis: No material adverse thesis is supported because no direct negative evidence is retained in the reviewed sources.

Why now: There is no evidenced near-term or durable why-now catalyst inside the retained 90-day evidence window.

Caveats: Reviewed evidence references but provides no representative article. Potentially positive older context may be stale or superseded; recency cannot be validated. No retained evidence after recent evidence window.

Thesis: No material adverse evidence is available in the reviewed sources, so there is no supported risk thesis beyond generic startup and execution uncertainty, which is insufficient under the evidence rules.

Why now: No within the recent evidence window evidence are available after filtering, so there is no near-dated trigger or state change that can be scored from the local reviewed sources.

Caveats: Membership support references article, but that article content is not available here for direct citation. Coverage debug shows zero evidence after recent evidence window. A positive thesis requires positive evidence, not just category fit or membership rationale.

Thesis: No material negative evidence is available. The main risk is that space may remain too small a contributor within Fujitsu's broader business to drive a distinct thesis, but this is an inference from the reviewed sources' boundary ambiguity rather than direct adverse evidence (: and; not provided in reviewed sources).

Why now: An MOU in SDA could matter over a 1 year+ horizon if it converts into deployments or service revenue, but the reviewed sources offers no direct dated evidence inside recent evidence window and no article to validate timing.

Caveats: Large diversified company; reviewed sources does not show materiality of space effort. MOU is weaker than signed commercial contract revenue evidence. No direct article content or is available in reviewed sources.

Thesis: No reviewed sources-supported adverse thesis is available. There is also no material direct negative evidence after the 90-day recent evidence window.

Why now: There is no current catalyst in the reviewed sources. Coverage shows 32 article IDs considered but zero article IDs after recent evidence window and zero evidence after recent evidence window, so recency-based ranking is not supported.

Caveats: Phase2 rationale says only generic stock-screener style article context was available, citing article IDs, and, but no were provided in the reviewed sources. Evidence recent evidence review shows no current evidence was retained and undated_rows_kept = 0. Without for the cited membership-support articles, they cannot be used as factual thesis evidence under the citation requirement.

Thesis: Insufficient retained local evidence within the 90-day recent evidence window to support a material adverse thesis.

Why now: No company-specific dated evidence were retained after the 90-day recent evidence window cutoff of March 29, 2026, so there is no current catalyst basis in the reviewed sources.

Caveats: Reviewed evidence shows 64 articles considered but 0 article IDs after recent evidence window and 0 evidence retained. Membership support cited article IDs: and: but no article summaries or retained evidence are provided in these reviewed sources, so no factual thesis claims can be grounded from them.

Thesis: No material adverse evidence is retained. The main limitation is that the reviewed sources does not prove the scale, growth, or competitiveness of GS Yuasa's space exposure.

Why now: There is no verified near-term catalyst, but the reviewed sources' phase-2 rationale references saying GS Yuasa was named as a key player in a space battery market report. Without, timing detail, or retained evidence, recency is uncertain.

Caveats: The rationale cites, but no or retained article text is provided. Being listed as a key player in a market report is weaker than direct contract, launch, or financial evidence. No retained evidence remain after the 90-day recent evidence window.

Thesis: Government concentration or defense-program dependence could be a risk, but the reviewed sources contain no direct negative evidence within the available recent evidence window.

Why now: There is no available post-recent evidence window evidence in the reviewed sources to establish a current catalyst or changed business state.

Caveats: No evidence available after recent evidence window. Cannot rely on membership rationale alone for direction.